Table 4.
Warfarin | Hemophilia | Hemophilia With Inhibitor | VWD | |
---|---|---|---|---|
Peak of acceleration | 42.8 (38.0-49.4) | 53.9a (44.1-66.5) | 112b (69.0-120) | 46.7 (32.5-59.5) |
Height of acceleration-1 | 421 (162-499) | 237 (161-354) | 25.3b (20.9-33.5) | 397 (360-510) |
Height of acceleration-2 | 54.0 (46.7-73.2) | 93.7 (57.2-167) | 5.01b (3.90-5.80) | 241c (176-257) |
Width of acceleration-1 | 11.6 (9.10-20.1) | 20.0a (15.7-28.0) | 43.2a (23.1-88.7) | 13.4 (10.4-22.1) |
Width of acceleration-2 | 58.1 (48.2-86.8) | 49.4 (35.0-195) | 210 (40.0-283) | 41.8 (35.6-300) |
Peak of velocity | 103 (75.4-150) | 64.9a (52.2-85.0)) | 154.3 (83.8-219) | 52.4a (36.8-72.4) |
Height of velocity | 183 (117-216) | 155 (113-217) | 27.9c (24.7-50.7) | 209 (182-485) |
Width of velocity | 72.2 (61.1-99.6) | 64.0 (50.1-100) | 234 (52.9-316) | 52.0 (43.4-100) |
Peak of ½ fibrin formation | 51.9 (44.3-88.5) | 66.2 (54.4-104) | 159b (118-223) | 53.8 (37.9-73.7) |
Height of ½ fibrin formation | 246 (188-317) | 443b (296-578) | 502a (252-870) | 302 (182-336) |
Abbreviations: APTT, activated partial thromboplastin time; VWD, von Willebrand disease; Warfarin, patients treated with warfarin.
a P < .05 compared with patients treated with warfarin.
b P < .01 compared with patients treated with warfarin.
c P < .001 compared with patients treated with warfarin.